SGLT2 Inhibitors Show No Increased UTI Risk in RA and Diabetes

Sodium-glucose cotransporter-2 (SGLT2) inhibitor use among patients with rheumatoid arthritis (RA) and diabetes is not associated with a clear increase in overall urinary tract infection (UTI) risk, according to study results…